Telemus Capital’s Emergent Biosolutions EBS Stock Holding History

Telemus Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,521	Closed	-$249K	–	399
2020 Q3	$249K	Buy	+2,521	New	+$272K	0.02%	392

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Telemus Capital's EBS Position: Q4 2020 in Review

Telemus Capital sold out of Emergent Biosolutions (EBS) in Q4 2020, closing a stake of 2,521 shares — an estimated $249K sold.

Telemus Capital first reported a position in EBS in Q3 2020 and held it in 1 quarter. The position peaked at $249K in Q3 2020. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

Telemus Capital reported no remaining Emergent Biosolutions position as of Q4 2020 after selling out during the quarter.
Telemus Capital sold 2,521 Emergent Biosolutions shares in Q4 2020, an estimated $249K.
Telemus Capital first reported a position in Emergent Biosolutions in Q3 2020 and held it in 1 quarter.
Telemus Capital's Emergent Biosolutions position peaked at $249K in Q3 2020.
353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on Telemus Capital's 13F filing for Q4 2020, filed 28 Jan 2021.